Provided by Tiger Trade Technology Pte. Ltd.

CALCIMEDICA

2.10
+0.10005.00%
Post-market: 2.100.00000.00%19:58 EDT
Volume:113.72K
Turnover:241.33K
Market Cap:14.34M
PE:-0.32
High:2.22
Open:2.02
Low:2.02
Close:2.00
52wk High:36.00
52wk Low:2.00
Shares:6.83M
Float Shares:3.96M
Volume Ratio:0.73
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.6528
EPS(LYR):-9.8500
ROE:-365.70%
ROA:-63.58%
PB:2.60
PE(LYR):-0.21

Loading ...

CalciMedica Announces FDA Alignment on Phase 2B Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

THOMSON REUTERS
·
Jul 29

CalciMedica - Plans Phase 1B Trial for Auxora in Pah with Data Expected Mid-2027

THOMSON REUTERS
·
Jul 29

CalciMedica Inc: Continues to Advance Preparations for Phase 2B Trial

THOMSON REUTERS
·
Jul 29

CalciMedica - FDA Aligns on Phase 2B Primary Endpoint of New-Onset Severe Respiratory Failure

THOMSON REUTERS
·
Jul 29

Calcimedica - Prospectus Covers Resale of up to 56,020,287 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jul 25

Calcimedica Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Calcimedica Files Initial Beneficial Ownership Statement for Alafi Capital Co LLC

Reuters
·
Jul 11

Calcimedica Files Form 3 Initial Beneficial Ownership Statement for Director Evgeny Zaytsev

Reuters
·
Jul 08

CalciMedica Announces Board Expansion and Leadership Transition

TIPRANKS
·
Jul 08

Calcimedica Names Evgeny Zaytsev to Board as Director Expands to Eight Members

Reuters
·
Jul 08

Calcimedica Director Fred A. Middleton Acquires 248,972 Common Shares Worth $200,000

Reuters
·
Jun 29

CalciMedica Advances Auxora After Favorable FDA Safety Review

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)

TIPRANKS
·
Jun 25

CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review

MT Newswires Live
·
Jun 24

CalciMedica Amends Loan, Issues New Equity Warrants

TIPRANKS
·
Jun 24

CalciMedica announces $49M private placement

TIPRANKS
·
Jun 24

Calcimedica - Proceeds to Support Phase 1B Auxora Study in Pah and Cm5480 Ind Clearance, Data Expected Mid-2027

THOMSON REUTERS
·
Jun 24

Calcimedica - Anticipates Cash Runway into Second Half of 2027 with Upfront Proceeds

THOMSON REUTERS
·
Jun 24

Calcimedica Announces Private Placement Financing for up to Approximately $49 Million to Advance Pulmonary Hypertension Program

THOMSON REUTERS
·
Jun 24

Calcimedica - FDA Review Allows Calcimedica to Continue Dosing Auxora in Kourage Trial

THOMSON REUTERS
·
Jun 24